Brigid Boland, MD
Gastroenterology · San Diego, CANPI 1902069446
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,446 of the $61,745 with a category attached, or 76.8%. It is spread thinly across 18 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2023 at $21,198 and has fallen 57.3% since, to $9,059 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $546.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$14K
- E.r. Squibb & Sons, L.L.C.$13K
- Pfizer$12K
- Celltrion USA Inc.$8K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Bristol Myers Squibb$5K
- plus $5K from 12 others
Across 170 payments — averaging $13,617 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.6M
- AbbVie$500K
- Kyowa Kirin, Inc.$98K
- Roche Products Limited$48K
- Astrazeneca UK Limited$39K
- Bristol Myers Squibb$35K
- plus $44K from 3 others
What the payments were for
- Consulting fees$47,44677%
- Speaking & faculty fees$5,93010%
- Travel & lodging$3,9636%
- Food & beverage$4,4007%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $14,255 |
| E.r. Squibb & Sons, L.L.C. | 9 | $13,182 |
| Pfizer | 11 | $11,805 |
| Celltrion USA Inc. | 4 | $7,566 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $5,172 |
| Bristol Myers Squibb | 28 | $5,170 |
| AbbVie | 15 | $2,888 |
| Sanofi | 1 | $1,098 |
| Johnson & Johnson | 2 | $161 |
| Cook Medical LLC | 2 | $109 |
| Medtronic | 4 | $100 |
| ERBE USA Inc | 2 | $55 |
| Steris Corporation | 2 | $39 |
| AstraZeneca | 1 | $38 |
| Boston Scientific | 1 | $35 |
| Fujifilm Healthcare Americas Corporation | 1 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
| Olympus America Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,745 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 56 | $1,485,250 |
| GattexTeduglutide | 15 | $687,544 |
| Humira(Cf) PenAdalimumab | 32 | $406,105 |
| Skyrizi On-BodyRisankizumab-Rzaa | 17 | $329,274 |
| RinvoqUpadacitinib | 43 | $265,771 |
| XeljanzTofacitinib Citrate | 14 | $115,789 |
| Mesalamine | 34 | $35,400 |
| ViokaceLipase/Protease/Amylase | 12 | $13,904 |
| Balsalazide Disodium | 19 | $3,915 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 36 | $2,417 |
| Budesonide EcBudesonide | 20 | $1,743 |
| LoperamideLoperamide Hcl | 12 | $839 |
| Azathioprine | 17 | $633 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 13 | $616 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $161 | $1,485,25056 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $5,172 | $687,54415 claims |
| AbbVieRinvoq | $2,888 | $265,77143 claims |
| PfizerXeljanz | $11,805 | $115,78914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in San Diego
- William SandbornSan Diego$340K
- David KunkelSan Diego$287K
- Naveen GaraSan Diego$178K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.